FDA official overseeing food policy and response to resign in wake of baby formula shortage

FDA official overseeing food policy and response to resign in wake of baby formula shortage


A sign for the Food and Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.

Sarah Silbiger | Getty Images

Frank Yiannas, a top official at the Food and Drug Administration in charge of the agency’s food policy and response office, announced Wednesday that he is stepping down from his role as deputy commissioner.

Yiannas was among the FDA officials leading the agency as it navigated its way through last year’s infant formula shortage after Abbott Laboratories voluntarily shut down production at the country’s largest formula factory following reports that infants who consumed formula from the plant got sick.

His resignation comes days after Abbott Laboratories confirmed that the Justice Department was investigating the company over its Michigan baby formula plant.

“Today, I informed Commissioner [Robert] Califf that I will be resigning my position as Deputy Commissioner for the Office of Food Policy and Response effective February 24 ,” Yiannas tweeted. “I am honored to have served the American public, alongside each and every one of you, over these past four years.”

Since December of 2018, Yiannas has been involved in the development and rollout of policies related to food safety, including response to outbreaks, tracing foodborne illness investigations, product recalls and supply chain innovation.

Yiannas’ resignation announcement comes weeks after an expert panel issued a scathing report on its investigation of the FDA’s processes and organizational structure for its foods program. The panel criticized, among other things, a “culture, structure, and governance model” that detracts from the program’s effectiveness.

That investigation, was ordered by FDA Commissioner Robert Califf in July, following growing criticism that the agency had mishandled the formula crisis after illnesses were reported.

Yiannas’ resignation letter, obtained by the Washington Post, referenced inheriting a “decentralized structure” at the agency’s foods program he operated, which he said “significantly impaired FDA’s ability to operate as an integrated food team and protect the public.”

NBC News has reached out to Yiannas for comment.

In a statement, the FDA lauded Yiannas for his service on the agency’s leadership team, saying his efforts to tackle key initiatives helped “create a safer and more digital, traceable food system for our country.”

“The FDA remains committed to providing an update on steps to strengthen the Human Foods Program at the end of January and additional updates on the organizational structure, including how responsibilities of Mr. Yiannas’ position will be handled moving forward, by the end of February,” an FDA spokesperson said in a statement.





Source

Making U.S. biotech more competitive with China’s could help rare disease patients, experts say
Health

Making U.S. biotech more competitive with China’s could help rare disease patients, experts say

The growth of China’s biotechnology sector has been staggering. Beijing is pumping money into the industry, backing research efforts and helping launch a new wave of labs and incubators in the country. That’s a problem for the U.S. biotech industry and also affects rare disease patients who are waiting for a cure. Among the experts […]

Read More
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
Health

Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good morning from San Francisco! It’s day three of the annual JPMorgan Healthcare Conference – the biggest gathering of biotech and pharma execs, investors and analysts in […]

Read More
OpenAI acquires health-care technology startup Torch
Health

OpenAI acquires health-care technology startup Torch

OpenAI has acquired the health-care technology startup Torch, the company announced on Monday. Torch was building a “unified medical memory” for artificial intelligence that aimed to bring a patient’s health data, which is typically siloed and stored across a number of different vendors and formats, into one place. Torch’s employees will join OpenAI as part […]

Read More